In a recent article for OBN’s CONNECT magazine, UKI2S provides its insights into early stage investment for life science companies and the key things investors are looking for.
Seed stage funding is a crucial step for early stage life sciences companies in achieving long term success. It can provide essential support to overcome the challenges and pitfalls associated with getting a new business off the ground. However, early ventures pose risks for investors, such as incomplete management teams, technology development risk, an uncertain route to market, being too early for fully commercial sales, incomplete funding packages and lack of visibility on exit.
The UK Innovation & Science Seed Fund (UKI2S), formerly Rainbow Seed Fund, is one of the few funds that invests in ideas and early- stage technologies, kick-starting entrepreneurs’ ideas to launch science-based companies that can deliver important innovations. The seed fund invests at the earliest stages of technology development, including pre- company stages, from £25k to £1m. UKI2S is a patient capital fund, meaning it can invest for as long as it takes to take technology to a great exit. It’s also a high risk high growth fund and actively seeks big ideas across the universe of life sciences.
The full article can be read in the latest edition of CONNECT.